- Home
- COLL vs BALY Comparison
COLL vs BALY Comparison
Compare COLL & BALY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- BALY
- Stock Information
- Founded
- COLL 2002
- BALY 2004
- Country
- COLL United States
- BALY United States
- Employees
- COLL N/A
- BALY 10500
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- BALY Hotels/Resorts
- Sector
- COLL Health Care
- BALY Consumer Discretionary
- Exchange
- COLL Nasdaq
- BALY Nasdaq
- Market Cap
- COLL 910.2M
- BALY 794.7M
- IPO Year
- COLL 2015
- BALY N/A
- Fundamental
- Price
- COLL $30.00
- BALY $13.21
- Analyst Decision
- COLL Strong Buy
- BALY Hold
- Analyst Count
- COLL 5
- BALY 7
- Target Price
- COLL $43.60
- BALY $18.00
- AVG Volume (30 Days)
- COLL 444.8K
- BALY 363.4K
- Earning Date
- COLL 05-08-2025
- BALY 02-19-2025
- Dividend Yield
- COLL N/A
- BALY N/A
- EPS Growth
- COLL 43.56
- BALY N/A
- EPS
- COLL 1.86
- BALY N/A
- Revenue
- COLL $631,449,000.00
- BALY $2,481,783,000.00
- Revenue This Year
- COLL $20.00
- BALY $3.06
- Revenue Next Year
- COLL $3.93
- BALY N/A
- P/E Ratio
- COLL $16.09
- BALY N/A
- Revenue Growth
- COLL 11.41
- BALY 2.80
- 52 Week Low
- COLL $27.28
- BALY $9.74
- 52 Week High
- COLL $42.29
- BALY $18.38
- Technical
- Relative Strength Index (RSI)
- COLL 51.96
- BALY 42.04
- Support Level
- COLL $29.01
- BALY $11.75
- Resistance Level
- COLL $30.53
- BALY $18.29
- Average True Range (ATR)
- COLL 0.89
- BALY 1.80
- MACD
- COLL 0.04
- BALY -0.47
- Stochastic Oscillator
- COLL 62.91
- BALY 21.53
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About BALY Bally's Corporation
Ballys Corp is a casino entertainment company with a growing omnichannel presence, currently owning and managing approximately 15 casinos across 10 states, a golf course in New York, a horse racetrack in Colorado, and having access to nearly 18 OSB licenses in states. The recent acquisition of Aspers Casino in Newcastle, UK, further expands its international footprint and enhances its diverse entertainment offerings. It also owns Bally's Interactive International an interactive gaming operator, Bally Bet, a first-in-class sports betting platform, and Bally Casino, a growing iCasino platform. The casino operations include approximately 15,300 slot machines, 580 table games, and 3,800 hotel rooms.